You are here

talazoparib

What Pfizer Gets in Its $14 Billion Medivation Deal

What Pfizer Gets in Its $14 Billion Medivation Deal

Motley Fool

prostate cancer

Flag link:

Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer

Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer

Yahoo/Business Insider

prostate cancer

Flag link:

Buyout target Medivation says cancer drug could be "best in class"

Buyout target Medivation says cancer drug could be "best in class"

Yahoo/Reuters

PARP inhibitors

Flag link:

Medivation: It’s Not Just M&A

Medivation: It’s Not Just M&A

Barron's

Gilead Sciences

PARP inhibitors

Flag link:

3 Cancer Companies to Watch Closely in 2016

3 Cancer Companies to Watch Closely in 2016

Motley Fool

Clovis Oncology

Flag link:

Medivation Destined To Become A Biotech Behemoth As Low-Risk Pipeline Expands

Medivation Destined To Become A Biotech Behemoth As Low-Risk Pipeline Expands

Seeking Alpha

Flag link:

BioMarin sells its PhIII cancer drug to Medivation for $570M

BioMarin sells its PhIII cancer drug to Medivation for $570M

Fierce Biotech

Flag link: